The Combination of Bcl-2 Inhibitor Venetoclax and Mcl-1 Inhibitor MIK665 induces Cell Death in HCC Cells

被引：0
|
作者：
Walz, Franziska [1 ]
Michalski, Marlen [1 ]
Aschenbrenner, Elisabeth [1 ]
Mueller-Schilling, Martina [1 ]
Guelow, Karsten [1 ]
机构：
[1] Univ Klinikum Regensburg, Klin & Poliklin Innere Med 1, Regensburg, Germany
来源：
INTERNIST | 2022年 / 63卷 / SUPPL 3期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PS041
引用
收藏
页码：328 / 329
页数：2
相关论文
共 50 条
  • [31] Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells
    Luedtke, Daniel A.
    Niu, Xiaojia
    Pan, Yihang
    Zhao, Jianyun
    Liu, Shuang
    Edwards, Holly
    Chen, Kang
    Lin, Hai
    Taub, Jeffrey W.
    Ge, Yubin
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2017, 2
  • [32] Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells
    Daniel A Luedtke
    Xiaojia Niu
    Yihang Pan
    Jianyun Zhao
    Shuang Liu
    Holly Edwards
    Kang Chen
    Hai Lin
    Jeffrey W Taub
    Yubin Ge
    Signal Transduction and Targeted Therapy, 2
  • [33] Expanded T-cell clones in CLL persist during combination therapy with BCL-2 inhibitor Venetoclax
    Maass, C.
    Schilhabel, A.
    Chall, P.
    Al-Sawaf, O.
    Tausch, E.
    Darzentas, N.
    Stilgenbauer, S.
    Fischer, K.
    Eichhorst, B.
    Baldus, C. D.
    Hallek, M.
    Bruggemann, M.
    Ritgen, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 36 - 36
  • [34] KS18, an Mcl-1 inhibitor, triggers cell death and enhances the therapeutic efficacy of venetoclax in bortezomib-resistant multiple myeloma cells
    Al Odat, Omar S.
    Aloudat, Osama
    Nelson, Emily
    Budak-Alpogan, Tulin
    Jonnalagadda, Subash
    Chen, Yong
    Pandey, Manoj
    CANCER RESEARCH, 2024, 84 (06)
  • [35] Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer
    Zsuzsanna Valko
    Zsolt Megyesfalvi
    Anna Schwendenwein
    Christian Lang
    Sandor Paku
    Nandor Barany
    Bence Ferencz
    Anita Horvath-Rozsas
    Ildiko Kovacs
    Erzsebet Schlegl
    Veronika Pozonec
    Kristiina Boettiger
    Melinda Rezeli
    Gyorgy Marko-Varga
    Ferenc Renyi-Vamos
    Mir Alireza Hoda
    Thomas Klikovits
    Konrad Hoetzenecker
    Michael Grusch
    Viktoria Laszlo
    Balazs Dome
    Karin Schelch
    British Journal of Cancer, 2023, 128 : 1850 - 1861
  • [36] Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer
    Valko, Zsuzsanna
    Megyesfalvi, Zsolt
    Schwendenwein, Anna
    Lang, Christian
    Paku, Sandor
    Barany, Nandor
    Ferencz, Bence
    Horvath-Rozsas, Anita
    Kovacs, Ildiko
    Schlegl, Erzsebet
    Pozonec, Veronika
    Boettiger, Kristiina
    Rezeli, Melinda
    Marko-Varga, Gyorgy
    Renyi-Vamos, Ferenc
    Hoda, Mir Alireza
    Klikovits, Thomas
    Hoetzenecker, Konrad
    Grusch, Michael
    Laszlo, Viktoria
    Dome, Balazs
    Schelch, Karin
    BRITISH JOURNAL OF CANCER, 2023, 128 (10) : 1850 - 1861
  • [37] Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
    Punnoose, Elizabeth A.
    Leverson, Joel D.
    Peale, Franklin
    Boghaert, Erwin R.
    Belmont, Lisa D.
    Tan, Nguyen
    Young, Amy
    Mitten, Michael
    Ingalla, Ellen
    Darbonne, Walter C.
    Oleksijew, Anatol
    Tapang, Paul
    Yue, Peng
    Oeh, Jason
    Lee, Leslie
    Maiga, Sophie
    Fairbrother, Wayne J.
    Amiot, Martine
    Souers, Andrew J.
    Sampath, Deepak
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (05) : 1132 - 1144
  • [38] Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia (vol 7, pg 1, 2022)
    Zhang, Qi
    Riley-Gillis, Bridget
    Han, Lina
    Jia, Yannan
    Lodi, Alessia
    Zhang, Haijiao
    Ganesan, Saravanan
    Pan, Rongqing
    Konoplev, Sergej N.
    Sweeney, Shannon R.
    Ryan, Jeremy A.
    Jitkova, Yulia
    Dunner, Kenneth, Jr.
    Grosskurth, Shaun E.
    Vijay, Priyanka
    Ghosh, Sujana
    Lu, Charles
    Ma, Wencai
    Kurtz, Stephen
    Ruvolo, Vivian R.
    Ma, Helen
    Weng, Connie C.
    Ramage, Cassandra L.
    Baran, Natalia
    Shi, Ce
    Cai, Tianyu
    Davis, Richard Eric
    Battula, Venkata L.
    Mi, Yingchang
    Wang, Jing
    DiNardo, Courtney D.
    Andreeff, Michael
    Tyner, Jeffery W.
    Schimmer, Aaron
    Letai, Anthony
    Padua, Rose Ann
    Bueso-Ramos, Carlos E.
    Tiziani, Stefano
    Leverson, Joel
    Popovic, Relja
    Konopleva, Marina
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2022, 7 (01)
  • [39] The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells
    Booth, Laurence
    Roberts, Jane L.
    Avogadri-Connors, Francesca
    Cutler, Richard E., Jr.
    Lalani, Alshad S.
    Poklepovic, Andrew
    Dent, Paul
    CANCER BIOLOGY & THERAPY, 2018, 19 (03) : 239 - 247
  • [40] Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
    Bolomsky, Arnold
    Miettinen, Juho J.
    Malyutina, Alina
    Besse, Andrej
    Huber, Julia
    Fellinger, Stefanie
    Breid, Helene
    Parsons, Alun
    Klavins, Kristaps
    Hannich, J. Thomas
    Kubicek, Stefan
    Caers, Jo
    Huebl, Wolfgang
    Schreder, Martin
    Zojer, Niklas
    Driessen, Christoph
    Tang, Jing
    Besse, Lenka
    Heckman, Caroline A.
    Ludwig, Heinz
    BLOOD ADVANCES, 2021, 5 (20) : 4125 - 4139
12345